Fundraising Fox
Sanofi Ventures
Corporate VCCambridge · Seed–Late Stage · 20 people tracked
Also known as Sanofi
Find your way into Sanofi Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Ishaan Tewarie to introduce you to Kriti Subramanyam
You →Ishaan · together at MIT Hacking Medicine →Kriti
Ask Jamie Chen to introduce you to Meg Krench
You →Jamie · together at New England Venture Network →Meg
Ask Sam Okafor to introduce you to Pierre Gaudeaux
You →Sam · together at Smart Immune →Pierre
- Cris De Luca749 people can intro you
- Paulina Hill731 people can intro you
- Becca639 people can intro you
Sign up to find every way you can get introduced to Sanofi Ventures
- Your email: who you already know at Sanofi Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sanofi Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Sanofi Ventures serves as Sanofi's entry point into the innovation ecosystem, strategically investing in early-stage transformational science and technology at companies too early to partner with or acquire. It backs top-tier biotech and digital health companies focused on helping patients and transforming the practice of medicine. The fund invests across all stages of the private company lifecycle, from seed to Series B and beyond, frequently leading financings, serving on boards, and working alongside portfolio companies to build long-term value. Stated areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation, reflecting alignment with Sanofi's broader R&D strategy.
Source: firm website, verified Sep 26, 2026.
Team · 20 people
from the firm's website & curated & public directories
What they invest in
from 94 of 120 portfolio companiesBiotech ×79Healthtech ×58Medical Devices ×34Digital Health ×24AI & Machine Learning ×19Deep Tech ×19Longevity ×6Data & Infrastructure ×3
HQs:United States×60United Kingdom×3Switzerland×1Denmark×1Spain×1France×1
Who they back
founder profiles across 40 portfolio companiesFounding team size:solo founder×192 founders×143 founders×44+ founders×3
Where their founders studiedfrom 40 founders with education data
Massachusetts Institute of Technology ×3Columbia University ×2ETH Zürich ×2Harvard University ×2Northwestern University ×2Politecnico di Milano ×2Stanford University ×2The University of Texas at Austin ×2
What their founders studiedfrom 40 founders with field-of-study data
Life Sciences ×18Chemistry ×7Business & Management ×6Computer Science ×6Engineering ×6Medicine ×6Mathematics & Statistics ×2
Where their founders worked beforefrom 40 founders with career history
Atlas Venture ×3AstraZeneca ×2CytomX Therapeutics ×2HotSpot Therapeutics ×2IDEO ×2McKinsey & Company ×2Necessary Ventures ×2Neuron23 ×2
23 founders hold a PhD · 4 hold an MBA (of 43 with degree data)
Investments · 120 tracked
founders shown can be your intro pathBy year:2026 · 122025 · 122024 · 52023 · 52022 · 52021 · 62020 · 42018 · 22017 · 32016 · 22015 · 157 dated
Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)inBahram (Bob) Valamehr(President & Chief Executive Officer)inBahram Valamehr(President, Chief Executive Officer, and Director)in
BoardAmir Nashat(Director)in
Co-investorsVenrockFidelity InvestmentsOVP Venture PartnersPolaris Partners
Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.
BiotechCambridge, US
Robert Gould(Executive Officer, Director)inAlex C. Sapir(President and Chief Executive Officer, Director)in
BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)
Co-investorsForesite CapitalThird Rock Ventures
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+7 more
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Scott Koenig(Director)inEric Risser(President and Chief Executive Officer)in
Co-investorsHavencrest Capital ManagementRidgeback CapitalRiverVest Venture PartnersSaints CapitalLa CaisseTPG
Omada Health provides virtual-first, integrated care programs for chronic disease management, delivered as data-driven solutions for employers, health plans, and healthcare organizations.
Digital HealthHealthtechWellness & FitnessSan Francisco, US
Andrew DiMichelle(Executive Officer, Director)Adrian James(Executive Officer, Director)inSean Duffy(Executive Officer, Director)inWei-Li Shao(President)inSteve Cook(Chief Financial Officer)in
BoardJonathan Root(Director)in
Co-investorsaMoonAndreessen HorowitzBlackbird GiantsCanvas VenturesCivilization Ventures Management, LlcDesigner Fund+17 more
.jpeg){kind=logo}
Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments.
BiotechHealthtechMedical DevicesNew York, US
Matthew J. During(Executive Officer, Director)inJeremy M. Levin(Co-founder and Executive Chairman)inMeg Alexander(President & Chief Executive Officer)inCharles Carter(Chief Financial Officer)inVictoria Fort(Chief Strategy Officer)inPetra Kaufmann(Chief Medical Officer)in
Co-investorsBioBrit
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)5AM Ventures+2 more
Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.
BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US
Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)inAndrew Robbins(Chief Executive Officer, President and Director)inJohn Green(Chief Financial Officer)inEvan Kearns(Chief Legal Officer and Corporate Secretary)inCole Pinnow(Chief Commercial Officer)in
Co-investorsAtlas VentureF-Prime Capital
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatJason P. Hafler· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalMass General Brigham VenturesREDMILE+9 more
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSofinnova PartnersVIVES PartnersApollo Health VenturesSixty Degree Capital
Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases.
AI & Machine LearningBiotechDigital HealthJersey City, US
Cheng Zhang(CEO, Co-Founder)inMarcel van der Brug(Scientific Advisor, Co-Founder)inNick Johnson(Technology Advisor, Co-Founder)inDaniel Elgort(Chief Data and Analytics Officer)inLaura Carter(Chief Scientific Officer)inRobert Kim(Chief Medical Officer)in
Co-investorsaMoonLuma GroupInnovation EndeavorsCantos VenturesCatalio Capital Management, LPDuke Capital Partners+5 more
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsAccess BiotechnologyCanaan PartnersSV Health InvestorsSR One Capital ManagementBritish Business BankJanus Henderson Investors
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)in
Co-investorsNovartis Venture FundForbionVersant Ventures
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersAtlas Venture5AM Ventures
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedPureos BioventuresSunstone CapitalEQT Life Sciences+2 more
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut InnovationsOUP (Osage University Partners)+5 more
OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.
BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB
Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)inJonathan Hopper(Vice President, Platforms and Founder)inHsin Yung (Jason) Yen(Founder)inRos Deeganin
Co-investorsGV (Google Ventures)Oxford Science EnterprisesNorthpond Ventures
QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.
AI & Machine LearningBiotechDeep Tech
Co-investorsOrbiMedCreacion VenturesLilly Asia Ventures
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsAsabys PartnersNovartis Venture FundRoche Venture FundYsios CapitalCriteria Bio VenturesNew Enterprise Associates (NEA)+3 more
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)inLaia Crespo-Martin(Director)
Co-investorsMRL Ventures FundSV Health InvestorsAngelini VenturesDementia Discovery FundDolby Family VenturesMitsui Global Investment+2 more
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatChristopher Gagliardi· per SEC Form D
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAbingworth+2 more
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.
BiotechDigital HealthHealthtechMedical DevicesNew York, US
David B. Klein(Founder and CEO)inDavid Klein(Executive Officer, Director)inRandall Stanicky(Executive Officer)inAnthony Costello(Director)Bruce Robertson(Director)Douglas Langa(Director)
Board seatCris De Luca· per SEC Form D
Co-investorsAccelmed PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersHealth Catalyst CapitalHikma VenturesRevelation Partners+5 more
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Board seatJason P. Hafler· per SEC Form D
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)The Column GroupAbingworth+3 more
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Board seatJason P. Hafler· per SEC Form D
Co-investorsAccess BiotechnologyDigitalis VenturesAccess IndustriesAlexandriaAtlas Venture
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatJason P. Hafler· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSofinnova VenturesViking GlobalAgent Capital+11 more
Healthcare technology company delivering real-world evidence for life sciences companies, payers, and regulators.
Data & InfrastructureDigital HealthHealthtechNew York, US
Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)Kyle Armbrester(Chief Executive Officer)in
Co-investorsB Capital GroupB4 CapitalBlue Lion GlobalFlare Capital PartnersForesite CapitalLG Technology Ventures+6 more
.jpeg){kind=logo}
AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US
Anar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)
Co-investors1/1 Capitalabrdn plcAngelini VenturesFidelity InvestmentsJanus Henderson Investors
Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.
BiotechHealthtechCollege Park, US
John Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)
BoardNicholas Williams(Director)Moncef Slaoui(Director)Jon Edwards(Director)in
Co-investorsGRA VentureForbionMedicxiPitango
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Executive Officer, Director)in
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Co-investorsARCH Venture PartnersBain Capital Life SciencesGV (Google Ventures)Solas BioVenturesViking GlobalAccess Biotechnology+3 more
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundRiverVest Venture Partnersabrdn plcEQT Life Sciences
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestVida VenturesGoldman Sachs+1 more
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCMedical Excellence CapitalRA CapitalOpenSky Ventures
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsARCH Venture PartnersEaston CapitalRA CapitalThink+ Ventures Management, LlcWakestream Ventures
Branchlab offers an AI-driven platform for healthcare marketing that helps teams explore patient, HCP, and caregiver audiences without exposing Protected Health Information, then create, optimize, and activate those audiences across channels.
AI & Machine LearningHealthtechMarketing TechNew York, US
Joshua Walsh(Executive Officer, Director)Christopher Cagle(Executive Officer, Director)
BoardMichael Parkes(Director)inCarrie Williams(Director)inAndrew Bouldin(Director)in
Co-investorsAIX VenturesFCA Venture PartnersMcKesson VenturesNext VenturesNVP CapitalService Provider Capital+2 more
Carbon Health operates a chain of clinics offering urgent care, primary care, and chronic condition management, combining technology with in-person care to provide broader access to health services.
Digital HealthHealthtechMedia & Entertainment
Eren Bali(Founder)inGreg BurrellinTom Berry
Co-investors500 Emerging Europe500 Global515 VenturesAkkadian VenturesAnnex InvestmentsBuilders VC+29 more
HealthtechCambridge, US
Richard Whalley(Executive Officer, Director)James White(Executive Officer, Director)
BoardPatrick Flynn(Director)
Co-investorsWaterline VenturesQualcomm Ventures
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedRA CapitalHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Manhattan Beach, US
Peter Kim(Executive Officer, Director, Promoter)inFrancis Lam(Executive Officer, Director, Promoter)
BoardBill Geary(Director)inMohamad Makhzoumi(Director)in
Co-investorsFlare Capital PartnersGreen Bay VenturesNew Enterprise Associates (NEA)Shuttle Fund
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Co-investorsAtlas VentureEcoR1 CapitalFrazier Life SciencesRA CapitalRV Invest GmbHViking Global
Eligo Bioscience is a genetic engineering company pioneering synthetic biology approaches using CRISPR and phage biology to develop therapeutics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
David Bikard(Scientific Founder)Benoit Barteau(Scientific Cofounder)Nessan Bermingham(Scientific Cofounder)Laia Crespo-Martin(Scientific Cofounder)Xavier Duportet(CEO)
Co-investorsAgoranovNSG VenturesSeventure PartnersVIVES Partners
Empatica offers an FDA-cleared health monitoring platform combining medical wearables and digital biomarkers to collect continuous, clinical-quality health data from daily life.
AI & Machine LearningDigital HealthHealthtechMedical DevicesCambridge, US
Rosalind Picard(Founder and Director of the Affective Computing Group at the MIT Media Lab and Faculty Chair, MIT Mind+Hand+Heart Wellbeing Initiative)inMatteo Lai(Executive Officer, Director)inSimone Tognetti(Director)inLen Picard(Executive Officer, Director)inMario Scuderi(Director)
Co-investorsBlack Opal VenturesCDP Venture CapitalRA Capital
Enveda operates a drug-discovery platform that analyzes natural samples—primarily plant-derived molecules—using mass spectrometry, AI foundation models, and automated high-throughput labs to identify their chemical structures and therapeutic properties.
AI & Machine LearningBiotechDeep TechBoulder, US
Viswa Colluru, PhD(Founder)inViswa Colluru(Executive Officer, Director)inDaniel Wee(Executive Officer)
BoardRohit Sharma(Director)Zavain Dar(Director)inBruce Beutel(Director)
Co-investorsAir Street CapitalBoulder VenturesCatalio Capital Management, LPCox EnterprisesFPVHummingbird Ventures+18 more
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)
BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)
Co-investorsAlly Bridge Groupabrdn plcAngelini VenturesFidelity InvestmentsJanus Henderson Investors
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.
BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US
Christine Lemke(Executive Officer, Director)inDeborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein
BoardDavid Fleshman(Director)Rowan Chapman(Director)in
Co-investorsAsset Management CompanyB Capital GroupB4 CapitalCross Creek AdvisorsDementia Discovery FundFresco Capital+6 more
Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.
BiotechHealthtechMedical DevicesSan Francisco, US
Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)
Co-investorsForbionNovo HoldingsSofinnova Ventures
Formation.Fi is a decentralized finance platform built on Ethereum that enables users to participate in liquidity provision, yield farming, and asset swapping through automated strategies and smart contracts.
Crypto & Web3Fintech
Co-investorsGenblock CapitalAndreessen HorowitzLachy GroomSequoia CapitalThriveThrive Capital
Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesSaaSNew York, US
Ben Liu(CEO & Co-Founder)inLinhao Zhang(Co-Founder)inBenjamine Liu(Founder)in
BoardAlfred Lin(Director)inMichael Moritz(Director)inScott Kupor(Director)in
Co-investorsAndreessen HorowitzSequoia CapitalSam AltmanSection 32Thrive CapitalFelicis Ventures+11 more
GlycoMimetics is a company developing cancer therapies, aiming to advance treatment options for people living with cancer.
BiotechHealthtechWaltham, US
Co-investorsNew Enterprise Associates (NEA)
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more
A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investors7G BioVenturesCerity Partners VenturesColorcon VenturesHikma VenturesJDRF T1D Fund
Vaccine development platform using computationally designed synthetic virus-like particles
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
BoardPeter Kolchinsky(Director)in
Co-investorsQiming Venture Partners USARA CapitalViking GlobalQiming Healthcare
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)inAlbert M. Kim(Chief Medical Officer)in
Co-investorsAN Venture PartnersCatalio Capital Management, LPRA CapitalSV Health InvestorsCatalio Capital Management
Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.
BiotechHealthtechMedical DevicesSeattle, US
David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in
Co-investorsAisling CapitalAtlas VentureHM Venture PartnersOUP (Osage University Partners)Sanderling VenturesSPRINGROCK VENTURES+4 more
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)inMartin Edwards(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesSofinnova Ventures
The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.
Gaming
Co-investors5AM Ventures
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.
BiotechDeep TechHealthtechWaltham, US
Mark Vignola(Chief Financial Officer)inJonathan Violin(President)in
Co-investorsTCG CrossoverWellington ManagementVenrock
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)inKevin Raidy(Director)
Co-investors5AM VenturesAccess BiotechnologyAscenta CapitalForesite CapitalKern Capital, LLCWestlake Village BioPartners
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in
Co-investorsMRL Ventures FundYsios CapitalGilde HealthcareNovo HoldingsREDMILE
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesLongitude CapitalOberland CapitalPappas CapitalRiverVest Venture Partners
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)
Co-investorsAtlas VentureHatteras Venture PartnersLilly VenturesOmega FundsRoche Venture Fund
Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.
AI & Machine LearningBiotechDeep Tech
Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)
Co-investorsAtlas VentureDigitalis Ventures
Medisafe is a medication engagement platform that helps pharmaceutical companies connect with patients beyond the prescription and improve treatment adherence.
Digital HealthHealthtechMedical DevicesBoston, US
Rotem Shor(Founder)in
Co-investors7wire VenturesALIVE Israel HealthTech FundCorewell Health VenturesLool VenturesM VenturesOctopus Ventures+2 more
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)
BoardPaul Berns(Director)
Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedInvusPoint72Venrock Healthcare Capital Partners
Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.
BiotechDeep TechHealthtechLongevity
Rita Balice-Gordon(Founder)inJoachim Vilstrup(Head of Protein Chemistry and Structural Biology; scientific co-founder)inMichel Detheux(Chief Executive Officer & Board Director)inAnders Hinsby(Chief Operating Officer)inNiels Plath(Chief Scientific Officer)inJakob Busch-Petersen(Chief Development Officer)in
Co-investorsDroia VenturesSofinnova PartnersV-Bio Ventures
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Co-investorsage1Brace PharmaAtlas VenturePolaris PartnersSR One Capital Management
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactCatalio Capital ManagementInvusLeaps by BayerSixty Degree Capital
Co-investorsM VenturesSAV (Scale Asia Ventures)Vertex Ventures IsraelGrove VenturesS32
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsThe Column GroupSamsara BioCapital
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.
BiotechHealthtechMedical Devices
Pamela Conley(Founder)in
Co-investorsB Capital GroupB4 CapitalGlobal BioAccess FundMission BiocapitalDigitalis VenturesNorwest Venture Partners
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsabrdn plcAlexandriaB CapitalDigitalis VenturesGlobal BioAccess FundLeaps by Bayer+4 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+8 more
Owkin develops AI Scientist, an autonomous AI system that uses biological large language models and multimodal patient data to accelerate drug discovery for pharmaceutical and biotech companies.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSilicon Valley, FR
Thomas Clozel(Co-Founder and Chief Executive Officer)inGilles Wainrib(Co-Founder and Former Chief Scientific Officer)in
Co-investorsBridford Investments (Bridford Group)Cathay InnovationF-Prime CapitalFrstGV (Google Ventures)Alpha Intelligence Capital+2 more
Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
Co-investorsAvoro Capital AdvisorsF-Prime CapitalNew Enterprise Associates (NEA)Sofinnova Ventures
QuantHealth provides clinical trial design optimization tools that help pharmaceutical and biotech companies evaluate trial outcomes, competitive positioning, and enrollment feasibility to reduce development risk and accelerate timelines.
AI & Machine LearningBiotechDigital HealthHealthtech
Orr Inbar(Chief Executive Officer)inArnon Horevin
Co-investorsIsrael Innovation AuthorityATOORO FUNDEsplanade VenturesNina CapitalNovaCapitalPitango+1 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsALS Investment FundDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission Biocapital+8 more
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB InvestmentEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in
Co-investors5AM VenturesEpidarex CapitalF-Prime CapitalSofinnova Partners
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupAbingworthAdvent Life Sciences+11 more
Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine.
BiotechDigital HealthHealthtechMedical Devices
Tyler Van Horn(Chief Executive Officer)inDebra Weinstein(Chief Medical Officer)in
Co-investorsGlynn Capital ManagementGV (Google Ventures)LifeSci Venture PartnersLux CapitalInertia VenturesREDMILE
Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.
Co-investorsSofinnova PartnersInvusREDMILE
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersPICUS CAPITALSV Health InvestorsDementia Discovery FundFrazier Healthcare Partners+2 more
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB
Co-investorsCambridge Innovation CapitalF-Prime CapitalSofinnova PartnersDigitalis Ventures
Developer of next-generation insulin solutions
BiotechWaban, US
Richard Berenson(Executive Officer, Director, Promoter)David C. Sweeney(Director)
BoardTim Xiao(Director)inJohn Brooks(Mr. Brooks is the Chairman of the Board of Directors.)
Co-investorsDelos CapitalRobin Hood VenturesGreen Park & Golf VenturesJumpstart Ventures
Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines, with a focus on immunology and the immune system.
AI & Machine LearningBiotechHealthtech
Co-investorsMRL Ventures FundNew Enterprise Associates (NEA)Rho VenturesFJ Labs
Trial Library operates an AI-native platform that integrates clinical trials into routine care, activating providers, identifying eligible patients, and guiding them through the trial lifecycle.
AI & Machine LearningDigital HealthHealthtech
Co-investorsHow Women InvestLux CapitalNext VenturesOverwater Ventures LlcSeae VenturesSemperVirens Venture Capital+1 more
Ultragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases.
BiotechHealthtechMedical Devices
Co-investorsF-Prime CapitalPappas Capital
Unspun develops 3D weaving technology and software for apparel and textile manufacturing, enabling fast, automated, and low-waste garment production for brands and manufacturers.
Advanced ManufacturingCleantechClimate TechEmeryville, US
Walden Hoi Ming Lam(Executive Officer, Director)Beth Esponnette(Founder)inKevin Martin(Founder)inARNE ARENS(Executive Officer, Director)in
BoardMilo Werner(Director)inShuo Yang(Director)in
Co-investorsAlumni VenturesCity LightDCVC (Data Collective)E12 Venture Capital, LlcEvolution VenturesFifty Years+10 more
Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where a specific genetic mutation is the underlying cause.
BiotechHealthtechBoulder, US
Co-investorsWellington Management
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesHatteras Venture PartnersPappas CapitalAlexandriaGenesys CapitalJDRF T1D Fund+4 more
Aptar Digital Health is a division of Aptar Pharma that designs and manufactures drug delivery systems and digital health solutions for the pharmaceutical and healthcare industries.
Digital HealthHealthtechMedical DevicesSaaS
Co-investorsEisai Innovation, Inc.KaristaVesalius Biocapital Partners
Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.
AI & Machine LearningData & InfrastructureDefense TechTel Aviv
Amiad Daniel(Executive Officer, Director)Matan Peled(Director)in
BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)inThompson Hutton(Director)in
Co-investorsAlephFTV CapitalThompson Hutton, LLCJanus Henderson InvestorsPivotal Life SciencesQiming Venture Partners+3 more
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSR One Capital ManagementJanus Henderson InvestorsNovo Holdings+3 more
Zag Bio develops thymus-targeted bifunctional antibodies designed to induce central tolerance for treating autoimmune diseases.
BiotechDeep TechHealthtechMedical DevicesCambridge, US
Alan Crane(Founder & CEO)Diane Mathis(Co-founder)Joanne Lim(Co-founder)
Co-investorsLightspeed Venture PartnersMission BiocapitalPear VCPolaris Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Expansion TherapeuticsAliada TherapeuticsAliadatxAttoviaAvilarCurevoExpansionrxExpedition Therapeuticsi2O Therapeutics (AdvanCell Isotopes)Imbria PharmaceuticalsLatigoLysosomaltxMatchpointMemento MedicinesNavitorNeuroviaNextPointOdysseyOvid TherapeuticsSelectaSelecta BiosciencesTisento TherapeuticsVrataYumanityYumanity Therapeutics
Exits · 16
8 IPOs · 8 acquisitions · showing 14Fate TherapeuticsNASDAQ: FATEFulcrum TherapeuticsNASDAQ: FULCKymera TherapeuticsNASDAQ: KYMRMacrogenics IncNASDAQ: MGNXOmada HealthNASDAQ: OMDAOvidrxNASDAQ: OVIDQ32 BioNASDAQ: QTTBUnum TherapeuticsNASDAQ: COGTAliada Therapeuticsacq. by AbbVieCurevoacq. by Eli Lilly and CompanyLumena Pharmaceuticalsacq. by ShireProteostasis Therapeuticsacq. by Yumanity TherapeuticsTidal Therapeuticsacq. by SanofiVeraloxacq. by Cadrenal Therapeutics
Portfolio news
latest coverage across their companiesAbcuro · finsmes.com · Aug 18, 2026
Epicrispr Biotechnologies · finsmes.com · Aug 11, 2026
AdvanCell Isotopes · intelligence360.news · Aug 4, 2026
Q32 Bio · stocktitan.net · Jul 15, 2026
Draig Therapeutics · finsmes.com · Jul 14, 2026
Enveda Biosciences · enveda.com · Jul 8, 2026
Bionyra · finsmes.com · Jun 22, 2026
Frequently asked questions
- How many investments has Sanofi Ventures made?
- Sanofi Ventures has 120 tracked investments, 16 of which have exited, including 25 dated in the last 24 months.
- What stage does Sanofi Ventures invest at?
- Sanofi Ventures invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What is Sanofi Ventures's typical check size?
- Sanofi Ventures typically writes checks of $5M.
- What sectors does Sanofi Ventures focus on?
- Sanofi Ventures focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Sanofi Ventures located?
- Sanofi Ventures is headquartered in Cambridge, US.
- Does Sanofi Ventures lead rounds?
- Yes, Sanofi Ventures leads investment rounds.
- Who does Sanofi Ventures co-invest with?
- Sanofi Ventures most often shares deals with RA Capital, New Enterprise Associates (NEA), OrbiMed, among 224 tracked co-investors.
- What size deals does Sanofi Ventures back?
- Across 33 deals with disclosed amounts, Sanofi Ventures has joined rounds of $3.5M – $175M (median $73.8M).
Images
Co-investors · 40
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
▶28 more co-investors
ForbionAbingworthNovartis Venture FundSofinnova VenturesDolby Family VenturesRiverVest Venture PartnersS32The Column GroupMcKesson VenturesVersant VenturesYsios CapitalInkefRoche Venture FundJDRF T1D FundAdjuvant CapitalKhosla VenturesVertex Ventures IsraelNorthpond VenturesGrove VenturesFrazier Healthcare PartnersAccess IndustriesSemperVirens Venture CapitalPontifax Venture CapitalPureos BioventuresMC Healthcare VenturesClarus VenturesKurma PartnersFaber
Firms observed investing alongside Sanofi Ventures, from public investor directories. Shared companies are the overlap with Sanofi Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.